StemCyte gains FDA nod for cord blood therapy

25 November 2024

StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy.

Regenecyte, an allogeneic hematopoietic stem cell therapy, is derived from human umbilical cord blood and is approved for unrelated donor hematopoietic progenitor cell transplants. The therapy is designed to reconstitute the hematopoietic and immune systems in patients with inherited, acquired, or treatment-related hematopoietic disorders.

In addition to Regenecyte, the firm is advancing Phase II clinical trials investigating cord blood-derived therapies for long COVID and acute stroke, alongside exploring potential treatments for aging-related diseases and chronic fatigue syndrome.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK